Bryan Garnier - Carlsberg A/S (CARL A) H1 results slightly better than expected. Upgrade to 2023 profit expectations.

Report

Bryan Garnier

Nikolaas Faes

H1 results slightly better than expected. Upgrade to 2023 profit expectations.

Carlsberg published first half results this morning, with H1 revenue at DKK37,788m in line with consensus of DKK37,920, and EBIT at DKK6,286m, 2% ahead of the consensus at DKK6,171m.Organic revenue growth was 11.2% and across all regions: Western Europe +9.2%, Asia +11.7% and Central & Eastern

16/08/2023 1 EN

Underlying

Carlsberg A/S

See profile

DK0010181676 Nasdaq Nordic Copenhagen Denmark

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Nikolaas Faes

Other Reports on these Companies

Bryan Garnier

End of coverage

From 6 October 2023, we will no longer include in our research universe:AB InbevCarlsbergHeinekenMolson CoorsRoyal Unibrew

October 6, 2023 October 6, 2023 1 EN

Bryan Garnier

Positive Q1 trading statement

Carlsberg published a positive trading statement with figures that came in ahead of Heineken's last week. More importantly, both are showing continued strong revenue per hl growth which should be a key driver of profits in H2. Carlsberg’s organic growth for volume/revenue/revenue per hl was 2.4%/14

April 27, 2023 April 27, 2023 1 EN

Onward: Model Update

We update our financial model after Onward medical released FY 2023 results last week The rating remains unchanged with a Buy recommendation and EUR 20 PT.

17h / 45m 17h / 45m 1 EN

Cedric Rossi

Cedric Rossi

Hugo Boss: Weak China and month of April spoilt the mood

In our view, the sharp negative market reaction was triggered by subdued trends in China and April trends which were slightly below the Q1 top-line performance (+6% FX-n), on top of another tough comparison base (Q2 2023: +20% FX-n). Whilst FY24 outlook was reiterated, management's relatively cauti

18h / 33m 18h / 33m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis reports Q1, on track with US trial

Egetis reported Q1 2024 results with an operating loss of SEK (68.6m) and a cash position of SEK 251.7m. In the pipeline, the most important update has been to the status of the critical US phase 3 trial, where the company reported that 13/16 patients have been recruited, whereof 6 patients have co

18h / 33m 18h / 33m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

H1 results slightly better than expected. Upgrade to 2023 profit expectations.

End of coverage

Positive Q1 trading statement

Onward: Model Update

Hugo Boss: Weak China and month of April spoilt the mood

Egetis reports Q1, on track with US trial

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe